REFERENCES
1. Data on file. Millennium Pharmaceuticals, Inc.
2. Richardson P, Sonneveld P, Schuster M, et al.
Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed
multiple myeloma: Updated results of the APEX trial. Poster presented at the American Society of Hematology 47th Annual Meeting and Exposition: December 10-13, 2005; Atlanta, Ga.
3. Knudsen LM, Hjorth M, Hippe E for the Nordic Myeloma Study Group. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Eur J Haematol. 2000;65:175-181.
4. Knudsen L, Hippe E, Hjorth M, et al. Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. Eur J Haematol. 1994;53:207-212.
5. Kyle R, Gertz M, Witzig T, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.
6. Nievizky R et al. Relationship between quality of response to bortezomib and clinical benefit in multiple myeloma in the APEX and Summit studies. Abstract presented at the American Society of Hematology 48th Annual Meeting and Exposition, December 9-12, 2006.
7. Sood R, Carloss H, Kerr R, et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib: a phase IV, open-label trial. Poster presented at the 31st ESMO Congress, September 29-October 3, 2006.
8. Conner TM, Doan QD, LeBlanc AL, Walters IB, Beveridge RA. An observational, retrospective
analysis of retreatment with bortezomib of multiple myeloma (MM) patients. Abstract presented at the American Society of Hematology 48th Annual Meeting and Exposition: December 9-12, 2006.
9. Wolf JL, Richardson P, LeBlanc A, Battleman D, Walters I. Utility of bortezomib retreatment for patients with relapsed multiple myeloma. Abstract presented at the American Society of Hematology 48th Annual Meeting and Exposition:
December 9-12, 2006.
10. San Miguel J, Richardson P, Sonneveld P, et al. Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial. Abstract (#366) presented at: The American Society
of Hematology 47th Annual Meeting and Exposition; December 10-13, 2005; Atlanta, Ga.
11. National Cancer
Institute Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 3.0, December 2003.
12. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent
and effective antitumor agents. Cancer Res. 1999;59:2615-2622.
13. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake
of construction. Physiol Rev. 2002;82:373-428.
14. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular
mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101(4):1530-1534.
15. National Cancer Institute Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0, June 1999.
